Search Result

Pathways Recommended:	Immunology/Inflammation

Results for "

chronic renal inflammation model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Autophagy (3) Cadherin (1) Dipeptidyl Peptidase (4) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) NF-κB (1) Reactive Oxygen Species (ROS) (1) TGF-β Receptor (1)
By Research Areas:	Endocrinology (1) Inflammation/Immunology (5) Metabolic Disease (4)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-120371

CPUY192018 1 Publications Verification	Keap1-Nrf2 Apoptosis Reactive Oxygen Species (ROS) NF-κB	Inflammation/Immunology
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, with an IC₅₀ of 0.63 µM. CPUY192018 exhibits anti-inflammatory and antioxidant activities. CPUY192018 can activate the Nrf2-dependent antioxidant pathway and inhibit the NF-κB-related inflammatory response. CPUY192018 can be used in the research of inflammation-related diseases .

HY-117985B

Evogliptin tartrate DA-1229 tartrate	Dipeptidyl Peptidase Autophagy	Metabolic Disease Inflammation/Immunology
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-117985A

Evogliptin hydrochloride DA-1229 hydrochloride	Dipeptidyl Peptidase	Metabolic Disease Endocrinology
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-117985

Evogliptin DA-1229	Dipeptidyl Peptidase Autophagy	Metabolic Disease Inflammation/Immunology
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-P11354

THR-123	TGF-β Receptor Apoptosis Interleukin Related Integrin Cadherin	Inflammation/Immunology
THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis .

HY-117985S

Evogliptin-d9 DA-1229-d₉	Isotope-Labeled Compounds Autophagy Dipeptidyl Peptidase	Metabolic Disease Inflammation/Immunology
Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

Cat. No.	Product Name	Target	Research Area

HY-P11354

THR-123	TGF-β Receptor Apoptosis Interleukin Related Integrin Cadherin	Inflammation/Immunology
THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis .

Cat. No.	Product Name	Chemical Structure

HY-117985S

Evogliptin-d9
Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

Evogliptin-d9

Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.